KLK3 and metastatic prostate carcinoma: Study population that included exclusively advanced and metastatic prostate cancer as published by Diallo et al. [8], Botcho et al. [9], and Ndoye et al. [11] displayed a higher mean PSA (1991.5 ng/ml, 1373.3 ng/ml, and 1447.6, respectively) and PSA range (5–216600 ng/ml).